22 Jan Utilization of Potentially Inappropriate Medications in Patients with Major Neurocognitive Disorders
Posted at 14:22h
in
Utilization of Potentially Inappropriate Medications in Patients with Major Neurocognitive Disorders
HC0099
Overview
Background
- Major neurocognitive disorders (MNCD), previously known as dementia, include a broad range of conditions, with Alzheimer disease being the most common subtype. Its prevalence is low in people younger than 65 but increases sharply with age. Data suggests a growing prevalence in Canada due to the ageing population.
- Antipsychotics, antidepressants, and anxiolytics medications are often used to manage the behavioural and psychological symptoms of dementia, though these carry important risks, including increased mortality and risks of cognitive impairment.
- Important gaps remain in our understanding of MNCD among older adults in Canada, as well as the use of potentially inappropriate medications (PIMs) in this population.
Objectives
- We will replicate a drug utilization study conducted by INESSS using data from Quebec to gather data from 6 additional provinces. The results from the Quebec study will be included into the overall findings.
- The objectives are to identify incident and prevalent cases of MNCD among older adults in each province between the fiscal years 2013–2014 and 2022–2023, and to describe patient characteristics and a set of indicators on the use of PIMs.